thyrotropin receptor (tshr)

VA-K-14 hydrochloride(VAK14 HCl) is a selective thyrotropin receptor (TSHR) antagonist (IC50= 12.3 μM) that inhibits TSHR stimulation by serum and monoclonal TSHR-stimulating antibodies from patients with GD and abrogates TSHR signaling.

ML-109 is a potent agonist of thyroid stimulating hormone receptor (TSHR) (EC50 of 40 nM)

NCGC00229600 is an allosteric inverse thyrotropin receptor (TSHR) agonist. NCGC00229600 inhibits both TSH and stimulating antibody activation of TSHRs endogenously and can be used in Graves' disease studies.

TSHR antagonist S37 is a selective and competitive antagonist of the thyrotropin receptor (TSHR).

ML224 (NCGC00242364) is a TSHR antagonist for the treatment of Graves' orbital disease and Graves' hyperthyroidism.

Org41841 is an agonist of luteinising hormone/chorionic gonadotropin receptor and thyroid stimulating hormone receptor (EC50s: 0.2 and 7.7 μM, respectively) and can be used to study hyperthyroidism.

D3-βArr (NCGC00379308) is a positive allosteric modulator for thyrotropin receptor (TSHR), which initiates translocation of β-Arr 1 (EC50: 11.6 μM) by direct TSHR activation.

TSHR antagonist S37a is a selective, orally bioavailable TSHR (thyroid-stimulating hormone receptor) antagonist that inhibits TSH-induced cyclic adenosine monophosphate (cAMP) in TSHR-expressing HEK 293 cells, suitable for studying Graves' orbitopathy.

TSHR antagonist S37b, the less potent enantiomer of TSHR antagonist S37a, exhibits minimal efficacy in inhibiting the thyrotropin receptor (TSHR). It is utilized in thyroid function research[1].

Anti-TSHR Antibody (M22) is a and highly specialized stimulating monoclonal antibody that targets the thyrotropin receptor (TSHR) to mimic the biological activity of thyroid-stimulating hormone and facilitate the measurable activation of cyclic AMP signaling pathways across various endocrine and immunological experimental models.